Search

everythinglearnresearchcommunity

for

Search:↓

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

Entospletinib effectively prevents eye and skin GVHD in mice.

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

JAK inhibitors might help treat alopecia areata.

Blocking certain immune signals can reduce skin damage from radiation therapy.

JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

JAK inhibitors show promise in treating difficult skin diseases.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

ALRN-6924 may prevent hair loss caused by chemotherapy.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Blocking IL-17 can reduce skin inflammation in a mouse model of pityriasis rubra pilaris.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.

ILC1-like cells can cause alopecia areata by affecting hair follicles.

The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.

JAK inhibitors are effective treatments for alopecia areata.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

IL-1β inhibits human hair follicle growth.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Anti-IL17A therapy reduced venous leg ulcer size by 64% without major side effects.

Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Blocking the protein CXCL12 with a specific antibody can increase hair growth in common hair loss conditions.

IL-27 can prevent hair loss in alopecia areata.